NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News

$8.84

-0.12 (-1.34%)

(As of 06/8/2023 ET)

Compare

Today's Range: $8.61
▼
$9.45
50-Day Range: $5.44
▼
$10.50
52-Week Range: $1.79
▼
$11.30

Volume: 71,600 shs
Average Volume: 84,830 shs
Market Capitalization: $297.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.00

Reneo Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 216.7% Upside
$28.00 Price Target
Short Interest: Healthy
2.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.31) to ($2.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

168th out of 986 stocks

Pharmaceutical Preparations Industry

74th out of 473 stocks

3.5

Analyst's Opinion

Consensus Rating
Reneo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.00, Reneo Pharmaceuticals has a forecasted upside of 216.7% from its current price of $8.84.
Amount of Analyst Coverage
Reneo Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.34% of the float of Reneo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Reneo Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Reneo Pharmaceuticals has recently increased by 121.11%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reneo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reneo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RPHM.

0.6

News and Social Media Coverage

Search Interest
Only 9 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
2 people have added Reneo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,000,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.61% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($2.31) to ($2.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reneo Pharmaceuticals is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reneo Pharmaceuticals is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reneo Pharmaceuticals has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reneo Pharmaceuticals (NASDAQ:RPHM) Stock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The company was incorporated in 2014 and is headquartered in Irvine, California.

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

May 31, 2023 | finance.yahoo.com

Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

May 31, 2023 | finance.yahoo.com

Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

June 9, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

May 26, 2023 | seekingalpha.com

RPHM Reneo Pharmaceuticals, Inc.

May 21, 2023 | finance.yahoo.com

Insiders Pour $1 Million Each Into These 2 ‘Strong Buy’ Stocks⁠ — Here’s Why Wall Street Thinks They Could Double (or More)

May 11, 2023 | msn.com

Reneo Pharmaceuticals: Q1 Earnings Insights

May 11, 2023 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

June 9, 2023 | UNKNOWN (Ad)

This Company Is Solving A Multi-Billion Dollar Problem!

This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!

May 9, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)

May 4, 2023 | marketwatch.com

Reneo Pharma Shares Drop 21% After $55M Public Offering Prices

May 4, 2023 | finance.yahoo.com

Reneo Announces Pricing of Public Offering of Common Stock

May 3, 2023 | msn.com

Reneo Pharmaceuticals launches stock offering, shares fall 10%

May 3, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock

April 5, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)

April 1, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Reneo Pharmaceuticals, Inc. Cut by Jefferies Financial Group (NASDAQ:RPHM)

March 29, 2023 | americanbankingnews.com

Reneo Pharmaceuticals (NASDAQ:RPHM) Announces Earnings Results

March 27, 2023 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 27, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies

March 9, 2023 | finance.yahoo.com

Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

March 3, 2023 | finance.yahoo.com

Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week

February 2, 2023 | finance.yahoo.com

Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

January 31, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

December 4, 2022 | finance.yahoo.com

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

November 8, 2022 | finance.yahoo.com

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

September 19, 2022 | nasdaq.com

Individual investors own 22% of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares but private equity firms control 60% of the company

See More Headlines

RPHM Price History

30 days | 90 days | 365 days | Advanced Chart

RPHM Company Calendar

Last Earnings: 3/27/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RPHM
CUSIP: N/A
CIK: 1637715
Web: reneopharma.com
Phone: 858-283-0280
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.00
High Stock Price Forecast: $31.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +216.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.06%
Return on Assets: -46.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.26
Quick Ratio: 9.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.08 per share
Price / Book: 2.17

Miscellaneous

Outstanding Shares: 33,660,000
Free Float: 27,631,000
Market Cap: $297.55 million
Optionable: Not Optionable
Beta: 1.24

Key Executives

Mr. Michael G. Grey (Age 69)
Founder & Exec. Chairman

Mr. Gregory J. Flesher (Age 52)
Pres, CEO & Director
Comp: $743.05k

Mr. Michael P. Cruse (Age 50)
Chief Operating Officer
Comp: $423.3k

Mr. Vineet R. Jindal (Age 44)
Consultant
Comp: $568.27k

Ms. Jennifer P. Lam
Principal Financial & Accounting Officer

Ms. Wendy S. Johnson M.B.A. (Age 70)
Consultant

Dr. Alejandro Dorenbaum M.D. (Age 61)
Chief Medical Officer

Ms. Lynn Purkins Ph.D.
Sr. VP of Clinical Operations

Ms. Ashley F. Hall J.D. (Age 50)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RPHM Stock - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPHM shares.
View RPHM analyst ratings or view top-rated stocks.
What is Reneo Pharmaceuticals' stock price forecast for 2023?: 2 brokers have issued twelve-month price targets for Reneo Pharmaceuticals' shares. Their RPHM share price forecasts range from $25.00 to $31.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 216.7% from the stock's current price.
View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts.
How have RPHM shares performed in 2023?: Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of the year. Since then, RPHM shares have increased by 279.4% and is now trading at $8.84.
View the best growth stocks for 2023 here.
Are investors shorting Reneo Pharmaceuticals?: Reneo Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 255,600 shares, an increase of 121.1% from the April 30th total of 115,600 shares. Based on an average trading volume of 107,500 shares, the short-interest ratio is currently 2.4 days. Currently, 2.3% of the shares of the stock are sold short.
View Reneo Pharmaceuticals' Short Interest.
When is Reneo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RPHM earnings forecast.
How were Reneo Pharmaceuticals' earnings last quarter?: Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Monday, March, 27th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.03.

When did Reneo Pharmaceuticals IPO?: (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
What is Reneo Pharmaceuticals' stock symbol?: Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."
Who are Reneo Pharmaceuticals' major shareholders?: Reneo Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.26%), ExodusPoint Capital Management LP (0.98%), Great Point Partners LLC (0.48%), Geode Capital Management LLC (0.38%), Federated Hermes Inc. (0.31%) and MAI Capital Management (0.21%). Insiders that own company stock include Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal.
View institutional ownership trends.
How do I buy shares of Reneo Pharmaceuticals?: Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reneo Pharmaceuticals' stock price today?: One share of RPHM stock can currently be purchased for approximately $8.84.
How much money does Reneo Pharmaceuticals make?: Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $297.55 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.
How can I contact Reneo Pharmaceuticals?: The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com.

This page (NASDAQ:RPHM) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial